Skip to main content
Erschienen in: Obesity Surgery 1/2016

01.01.2016 | Original Contributions

Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome

verfasst von: Sahruh Turkmen, Alebtekin Ahangari, Torbjörn Bäckstrom

Erschienen in: Obesity Surgery | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to evaluate the impact of Roux-en-Y gastric bypass (RYGB) surgery on metabolic syndrome-related variables in obese women with polycystic ovarian syndrome (PCOS).

Methods

Thirteen obese women with PCOS (Rotterdam criteria) who met the International Diabetes Federation criteria for metabolic syndrome and who qualified for RYGB were enrolled. Clinical examinations included ovarian ultrasonography and measurement of waist, hip, body mass index and blood pressure. Venous blood samples were taken at the visit before surgery to measure triglyceride, high-density lipoprotein, low-density lipoprotein, fasting glucose, glycated haemoglobin (HbA1c), serum progesterone, allopregnanolone, total testosterone and sex hormone-binding globulin (SHBG) levels. Six months after surgery, patients underwent the same examinations and provided blood samples to analyse the same variables.

Results

At 6 months after surgery, the metabolic syndrome-related variables improved in all patients, except in six patients with anovulatory menstrual cycles who still satisfied the criteria for metabolic syndrome. The metabolic variables normalised and serum progesterone and allopregnanolone levels increased in seven patients with ovulatory cycles. Testosterone and SHBG normalised in all patients at 6 months after surgery. Serum HDL and diastolic blood pressure did not change after surgery. Correlations were found among testosterone, progesterone, allopregnanolone, lipoproteins, triglyceride, fasting glucose and HbA1c levels, which was interpreted as progesterone and its metabolite allopregnanolone may contribute to metabolic abnormalities.

Conclusions

In PCOS patients, normalisation of metabolic dysfunction may be incomplete by 6 months after RYGB surgery, and the start of ovulatory menstrual cycles may indicate normalisation of metabolic dysfunction.
Literatur
2.
Zurück zum Zitat Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol. 2014;58:182–7.PubMedCrossRef Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol. 2014;58:182–7.PubMedCrossRef
3.
Zurück zum Zitat Escobar-Morreale HF. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008;9:2995–3008.PubMedCrossRef Escobar-Morreale HF. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008;9:2995–3008.PubMedCrossRef
4.
Zurück zum Zitat Panidis D, Farmakiotis D, Rousso D, et al. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89:899–906.PubMedCrossRef Panidis D, Farmakiotis D, Rousso D, et al. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89:899–906.PubMedCrossRef
5.
Zurück zum Zitat Vrbikova J, Cifkova R, Jirkovska A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003;18:980–4.PubMedCrossRef Vrbikova J, Cifkova R, Jirkovska A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003;18:980–4.PubMedCrossRef
6.
Zurück zum Zitat Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:266–72.PubMedCrossRef Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:266–72.PubMedCrossRef
7.
Zurück zum Zitat Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31(2):S8–S13. discussion S31-2.CrossRef Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31(2):S8–S13. discussion S31-2.CrossRef
8.
Zurück zum Zitat Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.PubMedCrossRef Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.PubMedCrossRef
9.
Zurück zum Zitat Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36:478–84.PubMed Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36:478–84.PubMed
10.
Zurück zum Zitat Carmina E, Napoli N, Longo RA, et al. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5.PubMedCrossRef Carmina E, Napoli N, Longo RA, et al. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5.PubMedCrossRef
11.
Zurück zum Zitat Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;15:CD003641. Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;15:CD003641.
13.
Zurück zum Zitat Perez-Torres I, Guarner V, El Hafidi M, et al. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem. 2011;11:1694–705.PubMedCrossRef Perez-Torres I, Guarner V, El Hafidi M, et al. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem. 2011;11:1694–705.PubMedCrossRef
14.
Zurück zum Zitat Alemany M. Steroid hormones interrelationships in the metabolic syndrome: an introduction to the ponderostat hypothesis. Hormones. 2012;11:272–89.PubMedCrossRef Alemany M. Steroid hormones interrelationships in the metabolic syndrome: an introduction to the ponderostat hypothesis. Hormones. 2012;11:272–89.PubMedCrossRef
15.
Zurück zum Zitat Netjasov AS, Vujovic S, Ivovic M, et al. Relationships between obesity, lipids and fasting glucose in the menopause. Srp Arh Celok Lek. 2013;141:41–7.PubMedCrossRef Netjasov AS, Vujovic S, Ivovic M, et al. Relationships between obesity, lipids and fasting glucose in the menopause. Srp Arh Celok Lek. 2013;141:41–7.PubMedCrossRef
16.
Zurück zum Zitat Golden SH, Kim C, Barrett-Connor E, et al. The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism. 2013;62:1313–22.PubMedPubMedCentralCrossRef Golden SH, Kim C, Barrett-Connor E, et al. The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism. 2013;62:1313–22.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Moran LJ, Teede HJ, Noakes M, et al. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:1004–10.PubMed Moran LJ, Teede HJ, Noakes M, et al. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:1004–10.PubMed
18.
Zurück zum Zitat Prior JC, Elliott TG, Norman E, et al. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014;9:e84698.PubMedPubMedCentralCrossRef Prior JC, Elliott TG, Norman E, et al. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014;9:e84698.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Kalkhoff RK. Metabolic effects of progesterone. Am J Obstet Gynecol. 1982;142:735–8.PubMed Kalkhoff RK. Metabolic effects of progesterone. Am J Obstet Gynecol. 1982;142:735–8.PubMed
20.
Zurück zum Zitat Holmberg E, Backstrom T, Johansson M, et al. Allopregnanolone induces a diurnally dependent hyperphagic effect and alters feeding latency and duration in male Wistar rats. Acta Physiol (Oxf). 2013;208:400–9.CrossRef Holmberg E, Backstrom T, Johansson M, et al. Allopregnanolone induces a diurnally dependent hyperphagic effect and alters feeding latency and duration in male Wistar rats. Acta Physiol (Oxf). 2013;208:400–9.CrossRef
21.
Zurück zum Zitat Genazzani AD, Strucchi C, Luisi M, et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:36–43.PubMedCrossRef Genazzani AD, Strucchi C, Luisi M, et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:36–43.PubMedCrossRef
22.
Zurück zum Zitat Alberti K, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.PubMedCrossRef Alberti K, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.PubMedCrossRef
23.
Zurück zum Zitat Rotterdam EA-SPcwg, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.CrossRef Rotterdam EA-SPcwg, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.CrossRef
24.
Zurück zum Zitat Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. Geneva: Wold Health Organization; 1999 [publ. no. WHO/NCD/NCS/99.2]. Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. Geneva: Wold Health Organization; 1999 [publ. no. WHO/NCD/NCS/99.2].
25.
Zurück zum Zitat Timby E, Balgard M, Nyberg S, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006;186:414–24.CrossRef Timby E, Balgard M, Nyberg S, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006;186:414–24.CrossRef
26.
Zurück zum Zitat Purdy RH, Moore Jr PH, Rao PN, et al. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnan-20-one in rat and human plasma. Steroids. 1990;55:290–6.PubMedCrossRef Purdy RH, Moore Jr PH, Rao PN, et al. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnan-20-one in rat and human plasma. Steroids. 1990;55:290–6.PubMedCrossRef
27.
Zurück zum Zitat Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol. 1976;124:92–6.PubMed Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol. 1976;124:92–6.PubMed
28.
Zurück zum Zitat Legro RS, Dodson WC, Gnatuk CL, et al. Effects of gastric bypass surgery on female reproductive function. J Clin Endocrinol Metab. 2012;97:4540–8.PubMedPubMedCentralCrossRef Legro RS, Dodson WC, Gnatuk CL, et al. Effects of gastric bypass surgery on female reproductive function. J Clin Endocrinol Metab. 2012;97:4540–8.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Jamal M, Gunay Y, Capper A, et al. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis. 2012;8:440–4.PubMedCrossRef Jamal M, Gunay Y, Capper A, et al. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis. 2012;8:440–4.PubMedCrossRef
30.
Zurück zum Zitat Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.PubMedCrossRef Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.PubMedCrossRef
31.
Zurück zum Zitat Shirling D, Ashby JP, Baird JD. Effect of progesterone on lipid metabolism in the intact rat. J Endocrinol. 1981;90:285–94.PubMedCrossRef Shirling D, Ashby JP, Baird JD. Effect of progesterone on lipid metabolism in the intact rat. J Endocrinol. 1981;90:285–94.PubMedCrossRef
32.
Zurück zum Zitat Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B. J Lipid Res. 1986;27:699–705.PubMed Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B. J Lipid Res. 1986;27:699–705.PubMed
33.
Zurück zum Zitat Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med. 1998;43:568–74.PubMed Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med. 1998;43:568–74.PubMed
34.
35.
Zurück zum Zitat Turkmen SAL, Cengiz Y. Effects of Roux-en-Y gastric bypass surgery on eating behaviour and allopregnanolone levels in obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;24:1–5. Turkmen SAL, Cengiz Y. Effects of Roux-en-Y gastric bypass surgery on eating behaviour and allopregnanolone levels in obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;24:1–5.
36.
37.
Zurück zum Zitat Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol. 2010;26:684–9.PubMedCrossRef Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol. 2010;26:684–9.PubMedCrossRef
38.
Zurück zum Zitat Linn ES. Clinical significance of the androgenicity of progestins in hormonal therapy in women. Clin Ther. 1990;12:447–55.PubMed Linn ES. Clinical significance of the androgenicity of progestins in hormonal therapy in women. Clin Ther. 1990;12:447–55.PubMed
39.
Zurück zum Zitat Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid metabolic studies before and after one year of treatment with ethynodiol diacetate in “normal” women. Fertil Steril. 1976;27:900–4.PubMed Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid metabolic studies before and after one year of treatment with ethynodiol diacetate in “normal” women. Fertil Steril. 1976;27:900–4.PubMed
40.
Zurück zum Zitat Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate metabolism in “normal” women using norgestrel for eighteen months. Fertil Steril. 1981;35:167–71.PubMed Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate metabolism in “normal” women using norgestrel for eighteen months. Fertil Steril. 1981;35:167–71.PubMed
41.
Zurück zum Zitat Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492–7.PubMedCrossRef Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492–7.PubMedCrossRef
42.
Zurück zum Zitat Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413–20.PubMedCrossRef Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413–20.PubMedCrossRef
43.
Zurück zum Zitat Elbers JM, Asscheman H, Seidell JC, et al. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab. 1997;82:2044–7.PubMed Elbers JM, Asscheman H, Seidell JC, et al. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab. 1997;82:2044–7.PubMed
44.
Zurück zum Zitat Lima MM, Pareja JC, Alegre SM, et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871–5.PubMedCrossRef Lima MM, Pareja JC, Alegre SM, et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871–5.PubMedCrossRef
Metadaten
Titel
Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome
verfasst von
Sahruh Turkmen
Alebtekin Ahangari
Torbjörn Bäckstrom
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 1/2016
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1729-0

Weitere Artikel der Ausgabe 1/2016

Obesity Surgery 1/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.